1.An Experience of High Dose Intravenous Immunoglobulin Therapy in Refractory Evans Syndrome.
Hee Sup KIM ; Won Sup SHIN ; Sang Il LEE ; Sang Woo KIM
Journal of the Korean Pediatric Society 1990;33(5):701-707
No abstract available.
Immunization, Passive*
;
Immunoglobulins*
2.Electrophysiological Changes in Lambert-Eaton Myasthenic Syndrome With Intravenous Immunoglobulin Therapy.
Sang Eun PARK ; Sang Won HA ; Ki Moo HONG ; Kyeung Mo AN ; Jeong Seon CHO ; Jeong Ho HAN ; Eun Kyoung CHO ; Doo Eung KIM
Journal of the Korean Neurological Association 2008;26(2):168-170
No abstract available.
Immunization, Passive
;
Immunoglobulins
;
Lambert-Eaton Myasthenic Syndrome
3.Pseudohyponatremia After Intravenous Immunoglobulin Therapy in a Patient With Guillain-Barre Syndrome.
Jinseok PARK ; Hyung Kyun IM ; Seok Ho LEE ; Won Ki PAEK ; Hyun Young KIM ; Seung Hyun KIM
Journal of the Korean Neurological Association 2010;28(4):332-334
No abstract available.
Guillain-Barre Syndrome
;
Humans
;
Immunization, Passive
;
Immunoglobulins
5.Non-Eczematous Vesiculobullous Skin Eruption after Stevens-Johnson Syndrome: Developed without Intravenous Immunoglobulin Therapy.
Jin A KIM ; Miri KIM ; Baik Kee CHO ; Hyun Jeong PARK
Annals of Dermatology 2014;26(6):789-790
No abstract available.
Immunization, Passive*
;
Skin*
;
Stevens-Johnson Syndrome*
6.Brain Tumor Immunology: Part II : Immunotherapy of Malignant Brain Tumors.
Yong Kil HONG ; Hyung Kyun RHA ; Chul Ku JUNG ; Sang Won LEE ; Tae Hoon JO ; Min Woo BAIK ; Suk Hoon YOON ; Joon Ki KANG ; Jin Un SONG ; Chang Rak CHOI
Journal of Korean Neurosurgical Society 1990;19(10-12):1389-1396
The prognosis of patients with malignant brain tumors has improved only slightly despite the combined use of surgery, radiation therapy, and chemotherapy. Immunotherapy offers some possibilities and hopes as a fourth modality for the treatment of cancers although it is still in the early stages of development. It is possible to classify immunotherapy within four generally accepted modalities : 1) restorative or nonspecific immunotherapy 2) adoptive immunotherapy 3) passive immunotherapy 4) active immunotherapy. The techniques of recombinant DNA, genetic engineering, cell fusion and hybridoma production, and molecular biology will make these therapeutic approaches more successful and as the clinical applications expand the skillful cancertherapist will become increasingly familiar with these treatments and the problems associated with their use.
Allergy and Immunology*
;
Brain Neoplasms*
;
Brain*
;
Cell Fusion
;
DNA, Recombinant
;
Drug Therapy
;
Genetic Engineering
;
Hope
;
Humans
;
Hybridomas
;
Immunization, Passive
;
Immunotherapy*
;
Immunotherapy, Active
;
Immunotherapy, Adoptive
;
Molecular Biology
;
Prognosis
7.Potential Therapeutics Against Flaviviruses.
Pyung Ok LIM ; Tae Hee LEE ; Kyung Min CHUNG
Journal of Bacteriology and Virology 2012;42(2):108-120
Flaviviruses have been important human pathogens after emerging and resurging flavivirus diseases over the past decades. Although effective therapeutic agents are not yet commercially available for use in humans, significant progress has been made toward developing effective therapeutics and treatments. Several studies have shown that antibodies against the flaviviral E and NS1 proteins play a central role in prophylaxis and/or treatment of flavivirus infection through passive immunization. In addition, many anti-flavivirals, including interferons, oligonucleotide-based platforms, and small compounds, have been developed and evaluated for their antiviral effects. This review provides an overview of various approaches to the development of anti-flaviviral candidates and new insights that could improve our strategies for designing effective therapeutics against flaviviruses.
Antibodies
;
Flavivirus
;
Flavivirus Infections
;
Humans
;
Immunization, Passive
;
Interferons
;
Proteins
8.A case of idiopathic thrombocytopenic purpura in pregnancy.
Mi Sook KIM ; Ho Joon HWANGBO ; Young Gi LEE ; Yoon Kee PARK ; Sung Ho LEE
Yeungnam University Journal of Medicine 1993;10(2):512-517
Idiopathic thrombocytopenic purpura is an uncommon illness but most common form of thrombocytopema in pregnancy. Corticosteroids, splenectomy, immunosuppressive drugs, and immunoglobulin therapy have been recommended for manaaement. The optimal method of delivery is controversial. We have experienced a case of idiopathic thrombocytopenic purpura diagnosed previously and managed with corticosteroid and vincrstine, which was followed by pregnancy, vaginal delivery and postpiirtum splenectomy.
Adrenal Cortex Hormones
;
Immunization, Passive
;
Pregnancy*
;
Purpura, Thrombocytopenic, Idiopathic*
;
Splenectomy
9.A Case of Pompholyx Following Intravenous Immunoglobulin Therapy in Guillain-Barre Syndrome.
Ji Hyun LEE ; Ji Su MOON ; Ji Won MIN ; Min Jeong KIM ; Bong Goo YOO ; Kwang Soo KIM
Journal of the Korean Neurological Association 2005;23(4):581-583
No abstract available.
Eczema, Dyshidrotic*
;
Guillain-Barre Syndrome*
;
Immunization, Passive*
;
Immunoglobulins*
10.Development of therapeutic antibodies for gastric and colorectal cancers.
Tian-tian ZHAO ; Na-na FAN ; Li LIN ; Qian DIN ; Jin-biao ZHAN
Journal of Zhejiang University. Medical sciences 2012;41(3):345-352
With the elucidation of structures and functions, antibodies are widely applied in the diagnosis and treatment of diseases. Today, therapeutic antibodies have played ever increasing roles in the treatment of cancers. In fact, there are over 20 monoclonal antibodies which have been approved by the U.S.Food and Drug Administration (FDA) for the therapeutic use in cancers. For the gastric and colorectal cancers, there are at least 9 antibodies have been approved for cancer therapy or for clinical trials. These antibody drugs target to tumor associate antigens and can destroy the cancer cells through several mechanisms such as antibody-dependent cell cytotoxicity, complement-dependent cytotoxicity, blockage of blood nutrition and crucial signaling pathways. With the progress in gene engineering technology, the diverse structures of antibodies can be created. In addition, the antibody-conjugates with radioisotopes, toxins and cytotoxins, are also designed for targeted therapy of gastric and colorectal cancers. In this article, we review the trends in the clinical development and application of antibody drugs for future research and development of the rapidly expanding therapeutic modality in gastric and colorectal cancers.
Antibodies
;
therapeutic use
;
Gastrointestinal Neoplasms
;
therapy
;
Humans
;
Immunization, Passive